Status:
TERMINATED
The Effect of SGLT2 Inhibitors on Cognitive Functions and BDNF Levels in Patients With Type 2 Diabetes
Lead Sponsor:
Goztepe Training and Research Hospital
Conditions:
Type2 Diabetes
Cognitive Impairment
Eligibility:
All Genders
60-80 years
Brief Summary
Cognitive impairment is a common complication in diabetes for various reasons. Although glycemic control improves cognitive impairment, different antidiabetic medications' effects on cognitive functio...
Detailed Description
Type 2 diabetes is a complex metabolic disorder that can cause serious damage to various organs. Impairment in cognitive functions is one of the common complications in patients with diabetes. Impairm...
Eligibility Criteria
Inclusion
- giving consent
- being 60 years old or older
- HbA1c concentrations between 6.5% and 8%
- using metformin as a single agent for at least 3 months
- diabetes age \<10 years
Exclusion
- having uncontrolled hypothyroidism, hyperthyroidism, or other diseases that may affect cognitive functions
- ketoacidosis or coma
- cerebrovascular disease or psychiatric disorder
- mental retardation, psychosis, dementia, brain trauma, epilepsy and other cerebral diseases
- alcohol or other substance abuse
- hearing loss
- Presence of diseases that will affect cognitive function such as chronic inflammatory diseases and respiratory system diseases
- chronic kidney failure (GFR \<45)
- sleep apnea syndrome
- malignancy
- using a sulfonylurea or glinide
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2021
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05341388
Start Date
March 1 2021
End Date
November 30 2021
Last Update
April 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul Medeniyet University Goztepe Research and Training Hospital
Istanbul, Turkey (Türkiye)